Erdomed 175 mg/5 ml powder for oral suspension Bulgaristan - Bulgarca - Изпълнителна агенция по лекарствата

erdomed 175 mg/5 ml powder for oral suspension

Анджелини Фарма България ЕООД - erdosteine - 175 mg/5 ml powder for oral suspension

Erdomed 225 mg powder for oral solution Bulgaristan - Bulgarca - Изпълнителна агенция по лекарствата

erdomed 225 mg powder for oral solution

Анджелини Фарма България ЕООД - erdosteine - 225 mg powder for oral solution

Erdomed  300 mg capsules, hard Bulgaristan - Bulgarca - Изпълнителна агенция по лекарствата

erdomed  300 mg capsules, hard

Анджелини Фарма България ЕООД - erdosteine - 300 mg capsules, hard

ENDOMETROX aerosolum spumescens 45 g аерозол Bulgaristan - Bulgarca - БАБХ (Българска агенция по безопасност на храните)

endometrox aerosolum spumescens 45 g аерозол

ВЕТПРОМ АД - Тилозин, Нитроксолин Има - аерозол - 750 000 iu/45 g; 0, 75 g/45 g - кобили

Oxervate Avrupa Birliği - Bulgarca - EMA (European Medicines Agency)

oxervate

dompe farmaceutici s.p.a. - recombinant human nerve growth factor - кератит - Офталмологични - Лечение на умерено (устойчиви епителните дефект) или тежки (язва на роговицата) невротрофичен кератит при възрастни.

Spikevax (previously COVID-19 Vaccine Moderna) Avrupa Birliği - Bulgarca - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - Ваксини - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Cevenfacta Avrupa Birliği - Bulgarca - EMA (European Medicines Agency)

cevenfacta

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - Антихеморагични - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.